Skip to main content

Table 2 Cognitive performance in the AD and control groups

From: Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer’s disease

Cognitive measures AD group (n = 30) Control group (n = 28) p value
MMSE 19.6 (5. 4) 28.4 (1.3) < 0.001
CASI 72.3 (14.0) 94.2 (4.5) < 0.001
ADAS-Cog 21.2 (10.4) 4.3 (2.8) < 0.001
COMT
 IR-T1 3.1 (1.7) 6.7 (1.4) < 0.001
 IR-T2 4.4 (1.6) 8.4 (1.2) < 0.001
 IR-T3 5.2 (1.5) 9.0 (0.9) < 0.001
 DR5 2.6 (2.1) 8.4 (1.2) < 0.001
 DR30 1.8 (2.0) 8.6 (1.0) < 0.001
  1. Data are presented as the mean (SD). p values were obtained using Student’s t tests for all data
  2. AD Alzheimer’s disease, MMSE Mini-Mental State Examination, CASI Cognitive Ability Screening Instrument, ADAS-Cog Alzheimer’s disease assessment scale–cognitive portion, COMT common object memory test, IR-T1 trial #1 of the immediate recall test, IR-T2 trial #2 of the immediate recall test, IR-T3 trial #3 of the immediate recall test, DR5 5-min delayed recall test, DR30 30-min delayed recall test